Ahmed Moin, Islam Md Deen, Aouad Phillip, Miskovic-Wheatley Jane, Touyz Stephen, Maguire Sarah, Cunich Michelle
MAINSTREAM The Australian National Centre for Health System Research and Translation, Sydney, New South Wales, Australia.
Boden Initiative, Charles Perkins Centre, Central Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
Int J Eat Disord. 2025 Jan;58(1):91-116. doi: 10.1002/eat.24302. Epub 2024 Nov 14.
This systematic review aims to comprehensively examine up-to-date evidence on the economic burden of eating disorders (EDs), both globally and by region.
A comprehensive search within five electronic databases, MEDLINE, Embase, CINAHL, PsycINFO, and EconLit, retrieved studies published from August 1, 2013, to June 30, 2024. Cost of illness (COI) studies, burden of disease, and other cost studies that reported costs in monetary values were included, and cost-effectiveness analysis studies were excluded. The quality of COI studies was assessed using Schnitzler's checklist. All cost estimates were converted into 2024 USD purchasing power parity (PPP). The PROSPERO registration number is CRD42022358136.
Twenty-six studies were identified for inclusion in this review, with 11 COI studies. The nationwide annual financial cost of EDs is estimated at PPP-USD 70.5 billion. Indirect costs contributed 70%-93% of total financial costs in the reviewed studies. Intangible costs (burden of disease) were estimated to be PPP-USD 355.6 billion. About half of the COI studies met 60% of the elements of Schnitzler's checklist, either completely or partly.
The number of COI studies has more than doubled in the last 10 years. Findings can inform healthcare administrators/policymakers to understand the magnitude of this burden when setting healthcare priorities and allocating resources to maximize social welfare. However, there are variations in the methods (thus quality) and perspectives used to assess this economic burden. Findings suggest that there is potential for enhancing the methodological rigor of future research.
本系统评价旨在全面审视全球及各地区饮食失调（ED）经济负担的最新证据。
在五个电子数据库MEDLINE、Embase、CINAHL、PsycINFO和EconLit中进行全面检索，获取2013年8月1日至2024年6月30日发表的研究。纳入疾病成本（COI）研究、疾病负担研究以及其他以货币价值报告成本的成本研究，排除成本效益分析研究。使用施尼茨勒清单评估COI研究的质量。所有成本估计均转换为2024年美元购买力平价（PPP）。PROSPERO注册号为CRD42022358136。
确定了26项研究纳入本评价，其中有11项COI研究。饮食失调的全国年度财务成本估计为705亿美元（购买力平价）。在所审查的研究中，间接成本占总财务成本的70%-93%。无形成本（疾病负担）估计为3556亿美元（购买力平价）。约一半的COI研究完全或部分符合施尼茨勒清单60%的要素。
在过去10年中，COI研究的数量增加了一倍多。研究结果可为医疗保健管理人员/政策制定者提供信息，以便他们在确定医疗保健优先事项和分配资源以实现社会福利最大化时了解这一负担的程度。然而，在评估这一经济负担所使用的方法（以及质量）和视角方面存在差异。研究结果表明，未来研究在加强方法严谨性方面具有潜力。
